Source-grounded facts extracted from Quince Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Christopher Lowe resigned as Chief Financial Officer at Quince Therapeutics, Inc..
“Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).”
Christopher Lowe resigned as member of the Board of Directors at Quince Therapeutics, Inc..
“On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the “Board”) of the Company, resigned as a member of the Board, effective immediately.”
Caryn McDowell departed as Chief Legal and Administrative Officer and Corporate Secretary at Quince Therapeutics, Inc..
“On May 20, 2022, the Company announced the departure of Caryn McDowell, the Company’s Chief Legal and Administrative Officer and Corporate Secretary, effective as of July 8, 2022 (the “Departure Date”).”
Dirk Thye was appointed as Chief Executive Officer at Quince Therapeutics, Inc..
“the appointment of Dirk Thye, M.D. as the Chief Executive Officer of the Company and as principal executive officer and a Class II director of the Company”
Michael Detke departed as Chief Medical Officer at Quince Therapeutics, Inc..
“Effective May 2, 2022 (the “Departure Date”), Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will step down from his position as the Chief Medical Officer.”
Marwan Noel Sabbagh was appointed as Director at Quince Therapeutics, Inc..
“On March 14, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Cortexyme, Inc. (the “Company”), the Board appointed Marwan Noel Sabbagh, M.D., to serve as a Class II director of the Company, effective immediately”
Christopher Lowe was appointed as Class III Director at Quince Therapeutics, Inc..
“On February 2, 2022, the Board appointed Mr. Lowe to serve on the Board as a Class III Director, to fill the vacancy resulting from Ms. Lynch’s resignation from the Board.”
Christopher Lowe was appointed as Interim Chief Executive Officer at Quince Therapeutics, Inc..
“On January 28, 2022, the Company appointed Christopher Lowe, the Company’s Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”), to serve as the Interim Chief Executive Officer (“Interim CEO”) of the Company.”
Stephen S. Dominy resigned as Director at Quince Therapeutics, Inc..
“Ms. Lynch and Dr. Dominy tendered their resignation from the Board, effective as of January 31, 2022.”
Casey C. Lynch resigned as Chairperson of the Board at Quince Therapeutics, Inc..
“Ms. Lynch and Dr. Dominy tendered their resignation from the Board, effective as of January 31, 2022.”
Stephen S. Dominy resigned as Chief Scientific Officer and a member of the Board at Quince Therapeutics, Inc..
“On February 1, 2022, the Company announced the departure of Casey C. Lynch, the Company’s President, Chief Executive Officer and Chairperson of the Board, and Stephen S. Dominy, M.D., the Company’s Chief Scientific Officer and a member of the Board, effective as of January 28, 2022 (the “Departure Date”).”
Casey C. Lynch resigned as President, Chief Executive Officer and Chairperson of the Board at Quince Therapeutics, Inc..
“On February 1, 2022, the Company announced the departure of Casey C. Lynch, the Company’s President, Chief Executive Officer and Chairperson of the Board, and Stephen S. Dominy, M.D., the Company’s Chief Scientific Officer and a member of the Board, effective as of January 28, 2022 (the “Departure Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.